Cencora, Inc. vs UBS Group AG: Strategic Comparison
Key Differences at a Glance
| Field | Cencora, Inc. | UBS Group AG |
|---|---|---|
| Revenue | $321.3B | $47.7B |
| Founded | 2001 | 1998 |
| Employees | 51,000 | 105,000 |
| Market Cap | $50.0B | $167.8B |
| Headquarters | United States | Switzerland |
Quick Stats Comparison
| Metric | Cencora, Inc. | UBS Group AG |
|---|---|---|
| Revenue | $321.3B | $47.7B |
| Founded | 2001 | 1998 |
| Headquarters | Conshohocken, Pennsylvania | Zurich and Basel, Switzerland |
| Market Cap | $50.0B | $167.8B |
| Employees | 51,000 | 105,000 |
Cencora, Inc. Revenue vs UBS Group AG Revenue — Year by Year
| Year | Cencora, Inc. | UBS Group AG | Leader |
|---|---|---|---|
| 2025 | $321.3B | $47.7B | Cencora, Inc. |
| 2024 | $294.0B | $42.3B | Cencora, Inc. |
| 2023 | $262.2B | $33.7B | Cencora, Inc. |
| 2022 | $238.6B | N/A | Cencora, Inc. |
Business Model Breakdown
Overview: Cencora, Inc. vs UBS Group AG
This in-depth comparison examines Cencora, Inc. and UBS Group AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cencora, Inc. on its own, evaluating UBS Group AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cencora, Inc. and UBS Group AG is widest.
On the headline numbers, Cencora, Inc. reports annual revenue of $321.3B against $47.7B for UBS Group AG, while their respective market capitalizations stand at $50.0B and $167.8B. Cencora, Inc. is headquartered in United States and UBS Group AG operates from Switzerland, and those different home markets shape how each company competes.
Cencora, Inc.: Cencora buys and distributes pharmaceuticals, specialty drugs, animal health products, and related healthcare supplies while also providing commercialization, logistics, and provider services through U.S. and international platforms.
UBS Group AG: UBS is less a traditional bank than a global private-wealth platform with a large Swiss banking base and selective investment banking capabilities. The Credit Suisse acquisition increased scale but made execution the central story.
Business Models: How Cencora, Inc. and UBS Group AG Make Money
Cencora, Inc. and UBS Group AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cencora, Inc. and UBS Group AG.
Cencora, Inc. business model: Cencora makes money primarily through high-volume pharmaceutical wholesale distribution. It also earns revenue from specialty distribution, provider services, international distribution, biopharma logistics, commercialization services, and animal-health distribution.
UBS Group AG business model: UBS makes money from wealth management fees, advisory, lending, Swiss retail and corporate banking, asset management fees, investment banking advisory and capital markets activity, and trading. Wealth management provides the strategic core because asset-based fees recur as long as client assets remain on the platform.
Competitive Advantage: Cencora, Inc. vs UBS Group AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cencora, Inc. stack up against those of UBS Group AG.
Cencora, Inc. competitive advantage: Cencora's competitive advantage is scale in regulated healthcare distribution. Its national and international distribution footprint, provider relationships, manufacturer services, specialty logistics, and working-capital discipline create advantages that are difficult for smaller distributors to copy.
UBS Group AG competitive advantage: UBS's advantage is the combination of Swiss banking trust, global ultra-high-net-worth coverage, more than USD 7 trillion in invested assets, and the ability to serve clients across wealth management, lending, capital markets, and asset management.
Growth Strategy: Where Cencora, Inc. and UBS Group AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Cencora, Inc. and UBS Group AG each plan to expand from here.
Cencora, Inc. growth strategy: Cencora's strategy is to protect core U.S. distribution scale while expanding specialty, international healthcare solutions, biopharma commercialization, cold-chain logistics, and services that are more valuable to manufacturers and providers than basic wholesale movement.
UBS Group AG growth strategy: UBS is focused on integrating Credit Suisse, reducing duplicate costs, expanding global wealth management relationships, using technology to improve advisor productivity, growing asset management mandates, and keeping the investment bank focused on capital-light advisory and markets strengths.
Financial Picture: Cencora, Inc. vs UBS Group AG
A closer look at the financial trajectory of Cencora, Inc. and UBS Group AG rounds out the comparison.
Cencora, Inc.: Cencora reported $321.333 billion in revenue for fiscal 2025, up from $293.959 billion in fiscal 2024 and $262.173 billion in fiscal 2023. Net income attributable to Cencora was $1.554 billion in fiscal 2025, illustrating the core economics of pharmaceutical distribution: enormous revenue volume, tight margins, and careful working-capital management. The leadership story also changed. The 2025 Form 10-K lists Robert P. Mauch as President and Chief Executive Officer, while Steven H. Collis appears in transition-related exhibits after retiring from the CEO role.
UBS Group AG: UBS Group reported USD 7.8 billion in 2025 net profit attributable to shareholders and a CET1 ratio of 14.4%. UBS AG consolidated total revenues were USD 47.7 billion, up from USD 42.3 billion in 2024, as Credit Suisse consolidation and client activity reshaped the revenue base.
Company-Specific SWOT Notes
Cencora, Inc.
Cencora has one of the largest pharmaceutical distribution networks in the United States, supported by international healthcare services and specialty logistics.
Wholesale drug distribution produces enormous revenue but low percentage margins, so execution and working-capital discipline are critical.
Specialty logistics, provider services, commercialization support, and international healthcare solutions can deepen Cencora's manufacturer and provider relationships.
Customer concentration, reimbursement pressure, controlled-substance oversight, cybersecurity risk, and legal settlements can pressure earnings and cash flow.
UBS Group AG
UBS's advantage is the combination of Swiss banking trust, global ultra-high-net-worth coverage, more than USD 7 trillion in invested assets, and the ability to serve clients across wealth management, lending, capital markets, and asset management.
UBS wins when wealthy clients consolidate advice, custody, lending, markets access, and estate or tax-aware services with one global institution.
The biggest risk is execution failure in the Credit Suisse integration or regulatory capital changes that reduce the economic upside of the merger.
UBS is focused on integrating Credit Suisse, reducing duplicate costs, expanding global wealth management relationships, using technology to improve advisor productivity, growing asset management mandates, and keeping the investment bank focused on capital-light advisory and markets strengths.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Cencora, Inc. | Cencora, Inc. reports the larger revenue base ($321.3B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | UBS Group AG | Founded in 2001 vs 1998. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Cencora, Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | UBS Group AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | UBS Group AG | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Cencora, Inc. reports the larger revenue base ($321.3B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 2001 vs 1998. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Cencora, Inc. or UBS Group AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Cencora, Inc. vs UBS Group AG
Is Cencora, Inc. better than UBS Group AG?
Verdict: Between Cencora, Inc. and UBS Group AG, Cencora, Inc. is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Cencora, Inc. comes out ahead in this Cencora, Inc. vs UBS Group AG comparison.
Who earns more — Cencora, Inc. or UBS Group AG?
Cencora, Inc. earns more with $321.3B in annual revenue versus UBS Group AG's $47.7B. Cencora, Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — Cencora, Inc. or UBS Group AG?
Cencora, Inc. reported $321.3B, while UBS Group AG reported $47.7B. The revenue leader is Cencora, Inc. based on latest verified figures.
Cencora, Inc. revenue vs UBS Group AG revenue — which is higher?
Cencora, Inc. revenue: $321.3B. UBS Group AG revenue: $47.7B. Cencora, Inc. has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Cencora, Inc. Annual Filings (10-K, 8-K)
- Cencora, Inc. Corporate Website
- Cencora, Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- data.sec.gov
- cencora.com
- UBS Group AG Corporate Website
- UBS Group AG Annual Report 2025 - Revenue and Financial Data
- ubs.com
- ubs.com
- ubs.com